ScinoPharm Taiwan Ltd (台灣神隆) yesterday said it expects sales to grow steadily this year, but added that it plans to diversify its business from generic active pharmaceutical ingredients (API) to contract manufacturing and research services in a bid to avoid an intense price competition in the generic API market.
The Tainan-based pharmaceutical company reported revenue of NT$3.52 billion (US$114.3 million) for last year, inching up 0.2 percent from a year earlier.
However, thanks to cost controls, net profit rose 4.9 percent annually to NT$443 million, or earnings per share of NT$0.56, the company said.
Revenue from generic API accounted for 65 percent of total revenue, maintaining its top ranking, while combined revenue from contract manufacturing and research services made up 34 percent, company data showed.
ScinoPharm this year expects to gain regulatory approval in the US to supply generic APIs for a treatment for breast cancer and benign prostatic hyperplasia, as well as approvals in China and Japan for two other generic APIs, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) told an investors’ conference in Taipei.
“However, we found that the prices of generic APIs fell significantly due to intense competition, and we could not win over our peers in countries with lower manufacturing costs, such as India and China,” Lin said.
ScinoPharm’s revenue from generic APIs last year fell 5.6 percent annually to NT$75.8 million, but revenue from contract manufacturing and research services jumped 10.4 percent and 64.7 percent annually to NT$17.2 million and NT$22.4 million respectively, company data showed.
Instead of seeking more API clients, the company plans to expand its contract manufacturing and research services this year, in the hope of boosting revenue contribution from the two segments to 40 percent of overall revenue.
This year, the company aims to focus more on the markets in Japan and China, which offer faster growth opportunities, compared with slowing growth in the US and Europe, where opportunities are further constrained by large-scale mergers and acquisitions in the pharmaceuticals sector, ScinoPharm said.
ScinoPharm shares yesterday rose 1.14 percent to NT$26.7 in Taipei. They have advanced 10.56 percent since the beginning of this year, compared with the broader market’s 9.41 percent rise over the same period.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
Nvidia Corp CEO Jensen Huang (黃仁勳) today announced that his company has selected "Beitou Shilin" in Taipei for its new Taiwan office, called Nvidia Constellation, putting an end to months of speculation. Industry sources have said that the tech giant has been eyeing the Beitou Shilin Science Park as the site of its new overseas headquarters, and speculated that the new headquarters would be built on two plots of land designated as "T17" and "T18," which span 3.89 hectares in the park. "I think it's time for us to reveal one of the largest products we've ever built," Huang said near the
China yesterday announced anti-dumping duties as high as 74.9 percent on imports of polyoxymethylene (POM) copolymers, a type of engineering plastic, from Taiwan, the US, the EU and Japan. The Chinese Ministry of Commerce’s findings conclude a probe launched in May last year, shortly after the US sharply increased tariffs on Chinese electric vehicles, computer chips and other imports. POM copolymers can partially replace metals such as copper and zinc, and have various applications, including in auto parts, electronics and medical equipment, the Chinese ministry has said. In January, it said initial investigations had determined that dumping was taking place, and implemented preliminary
Intel Corp yesterday reinforced its determination to strengthen its partnerships with Taiwan’s ecosystem partners including original-electronic-manufacturing (OEM) companies such as Hon Hai Precision Industry Co (鴻海精密) and chipmaker United Microelectronics Corp (UMC, 聯電). “Tonight marks a new beginning. We renew our new partnership with Taiwan ecosystem,” Intel new chief executive officer Tan Lip-bu (陳立武) said at a dinner with representatives from the company’s local partners, celebrating the 40th anniversary of the US chip giant’s presence in Taiwan. Tan took the reins at Intel six weeks ago aiming to reform the chipmaker and revive its past glory. This is the first time Tan
RSS